Amicus Therapeutics Inc. (NASDAQ:FOLD)‘s stock had its “buy” rating reaffirmed by analysts at Chardan Capital in a note issued to investors on Tuesday.

A number of other equities research analysts have also recently issued reports on FOLD. Leerink Swann reiterated a “buy” rating and set a $17.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, November 8th. Cowen and Company reiterated an “outperform” rating and set a $15.00 target price on shares of Amicus Therapeutics in a research report on Tuesday, November 8th. Finally, Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $12.19.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at 8.32 on Tuesday. Amicus Therapeutics has a 1-year low of $4.98 and a 1-year high of $11.02. The company’s 50-day moving average is $7.82 and its 200 day moving average is $6.97. The firm’s market capitalization is $1.18 billion.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The firm had revenue of $2.10 million for the quarter, compared to analyst estimates of $1.71 million. On average, analysts expect that Amicus Therapeutics will post ($1.38) EPS for the current fiscal year.

WARNING: This piece of content was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2016/11/29/amicus-therapeutics-inc-fold-given-buy-rating-at-chardan-capital.html.

In related news, insider Hung Do sold 25,000 shares of the company’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $7.00, for a total transaction of $175,000.00. Following the completion of the sale, the insider now owns 583,453 shares of the company’s stock, valued at $4,084,171. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO William D. Baird III sold 20,500 shares of the company’s stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $8.00, for a total transaction of $164,000.00. Following the sale, the chief financial officer now directly owns 56,450 shares of the company’s stock, valued at approximately $451,600. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of FOLD. FMR LLC boosted its stake in Amicus Therapeutics by 1.6% in the second quarter. FMR LLC now owns 19,023,053 shares of the biopharmaceutical company’s stock valued at $103,865,000 after buying an additional 299,950 shares in the last quarter. Redmile Group LLC increased its position in shares of Amicus Therapeutics by 14.8% in the third quarter. Redmile Group LLC now owns 12,751,536 shares of the biopharmaceutical company’s stock valued at $94,361,000 after buying an additional 1,645,090 shares during the last quarter. Jennison Associates LLC increased its position in shares of Amicus Therapeutics by 53.6% in the third quarter. Jennison Associates LLC now owns 7,906,476 shares of the biopharmaceutical company’s stock valued at $58,508,000 after buying an additional 2,759,262 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Amicus Therapeutics by 8.1% in the second quarter. Vanguard Group Inc. now owns 7,033,500 shares of the biopharmaceutical company’s stock valued at $38,404,000 after buying an additional 524,050 shares during the last quarter. Finally, BlackRock Fund Advisors increased its position in shares of Amicus Therapeutics by 14.7% in the third quarter. BlackRock Fund Advisors now owns 6,634,693 shares of the biopharmaceutical company’s stock valued at $49,097,000 after buying an additional 849,379 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

5 Day Chart for NASDAQ:FOLD

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.